Oxidative mechanisms in nigral cell death in Parkinson's disease - PubMed (original) (raw)
Affiliations
- PMID: 9613715
Review
Oxidative mechanisms in nigral cell death in Parkinson's disease
P Jenner. Mov Disord. 1998.
Abstract
Oxidative stress may contribute to nigral cell death in Parkinson's disease based on postmortem investigations showing increased iron levels, decreased levels of reduced glutathione (GSH), and impaired mitochondrial function. This leads to oxidative damage because lipid peroxidation is increased in substantia nigra and there is a widespread increase in protein and DNA oxidation in the brain in Parkinson's disease. Nitric oxide (NO) may be one of the free radical species involved in nigral degeneration. NO is involved in the production of hydroxyl radicals resulting from MPP+-induced dopamine efflux in striatum. Mice treated with the neuronal nitric oxide synthase (NOS) inhibitor 7-nitroindazole show reduced toxicity to MPTP and knock-out mice lacking neuronal NOS show decreased MPTP susceptibility. In primates, 7-nitroindazole inhibits MPTP toxicity but this remains controversial because no protection is afforded by the nonspecific NOS inhibitor, L-NAME. Indeed, in Parkinson's disease itself, there is little evidence for nitric oxide's involvement in nigral pathology. A susceptibility factor for the development of Parkinson's disease may involve isoforms of cytochrome P450, some of which are found in the brain. CYP2EI, which is associated with free radical production and the formation of endogenous toxins, is selectively localized in nigral dopamine-containing cells. CYP2E1 metabolizes n-hexane leading to the formation of its neurotoxic metabolite 2,5-hexanedione which may explain cases of solvent-induced parkinsonism. Oxidative processes clearly contribute to the pathology of Parkinson's disease but are probably secondary to some other primary unidentified cause, presumably genetic or environmental. Nevertheless, their involvement may allow therapeutic intervention in the cascade of events associated with the progression of Parkinson's disease.
Similar articles
- What process causes nigral cell death in Parkinson's disease?
Jenner P. Jenner P. Neurol Clin. 1992 May;10(2):387-403. Neurol Clin. 1992. PMID: 1584181 Review. - The possible role of iron in the etiopathology of Parkinson's disease.
Youdim MB, Ben-Shachar D, Riederer P. Youdim MB, et al. Mov Disord. 1993;8(1):1-12. doi: 10.1002/mds.870080102. Mov Disord. 1993. PMID: 8419792 Review. - Iron metabolism and Parkinson's disease.
Hirsch EC, Faucheux BA. Hirsch EC, et al. Mov Disord. 1998;13 Suppl 1:39-45. Mov Disord. 1998. PMID: 9613717 Review. - Nitric oxide and reactive oxygen species in Parkinson's disease.
Tieu K, Ischiropoulos H, Przedborski S. Tieu K, et al. IUBMB Life. 2003 Jun;55(6):329-35. doi: 10.1080/1521654032000114320. IUBMB Life. 2003. PMID: 12938735 Review. - Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM, Ophof A, Broe M, Jensen PH, Kettle E, Fedorow H, Cartwright MI, Griffiths FM, Shepherd CE, Double KL. Halliday GM, et al. Brain. 2005 Nov;128(Pt 11):2654-64. doi: 10.1093/brain/awh584. Epub 2005 Jul 6. Brain. 2005. PMID: 16000336
Cited by
- Early-life exposure to methylmercury in wildtype and pdr-1/parkin knockout C. elegans.
Martinez-Finley EJ, Chakraborty S, Slaughter JC, Aschner M. Martinez-Finley EJ, et al. Neurochem Res. 2013 Aug;38(8):1543-52. doi: 10.1007/s11064-013-1054-8. Epub 2013 Apr 23. Neurochem Res. 2013. PMID: 23609499 Free PMC article. - The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine.
Bolt HM, Roos PH, Thier R. Bolt HM, et al. Int Arch Occup Environ Health. 2003 Apr;76(3):174-85. doi: 10.1007/s00420-002-0407-4. Epub 2003 Mar 1. Int Arch Occup Environ Health. 2003. PMID: 12690492 Review. - 1-methyl-4-phenylpyridinium-induced alterations of glutathione status in immortalized rat dopaminergic neurons.
Drechsel DA, Liang LP, Patel M. Drechsel DA, et al. Toxicol Appl Pharmacol. 2007 May 1;220(3):341-8. doi: 10.1016/j.taap.2007.02.002. Epub 2007 Feb 12. Toxicol Appl Pharmacol. 2007. PMID: 17395226 Free PMC article. - Complex deregulation and expression of cytokines and mediators of the immune response in Parkinson's disease brain is region dependent.
Garcia-Esparcia P, Llorens F, Carmona M, Ferrer I. Garcia-Esparcia P, et al. Brain Pathol. 2014 Nov;24(6):584-98. doi: 10.1111/bpa.12137. Epub 2014 Apr 14. Brain Pathol. 2014. PMID: 24593806 Free PMC article. - Parkinson's disease updates: Addressing the pathophysiology, risk factors, genetics, diagnosis, along with the medical and surgical treatment.
Prajjwal P, Flores Sanga HS, Acharya K, Tango T, John J, Rodriguez RSC, Dheyaa Marsool Marsool M, Sulaimanov M, Ahmed A, Hussin OA. Prajjwal P, et al. Ann Med Surg (Lond). 2023 Aug 8;85(10):4887-4902. doi: 10.1097/MS9.0000000000001142. eCollection 2023 Oct. Ann Med Surg (Lond). 2023. PMID: 37811009 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical